NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022
Chrysalyne D. Schmults(Dana-Farber Brigham Cancer Center), Rachel Blitzblau(Cancer Institute (WIA)), Sumaira Z. Aasi(Cancer Institute (WIA)), Murad Alam(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), James Andersen(City Of Hope National Medical Center), Brian C. Baumann(Barnes-Jewish Hospital), Jeremy S. Bordeaux(Cleveland Clinic), Pei-Ling Chen(Moffitt Cancer Center), Robert Chin(University of Colorado Cancer Center), Carlo M. Contreras(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Dominick J. DiMaio(Susan Thompson Buffett Foundation), Jessica M. Donigan(Fox Chase Cancer Center), Jeffrey M. Farma(Fox Chase Cancer Center), Karthik Ghosh, Roy C. Grekin(UCSF Helen Diller Family Comprehensive Cancer Center), Kelly L. Harms(University of Michigan), Alan L. Ho(Memorial Sloan Kettering Cancer Center), Ashley M. Holder(University of Colorado Cancer Center), John N. Lukens(University of Pennsylvania), Theresa Medina(University of Colorado Cancer Center), Kishwer S. Nehal(Memorial Sloan Kettering Cancer Center), Paul Nghiem(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Soohyung Park(University of California San Diego), Tejesh Patel(St. Jude Children's Research Hospital), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Jeffrey Scott(Sidney Kimmel Comprehensive Cancer Center), Aleksandar Sekulić, Ashok R. Shaha(Memorial Sloan Kettering Cancer Center), Divya Srivastava(Southwestern Medical Center), William G. Stebbins(Breast Cancer Research Foundation), Valencia D. Thomas(The University of Texas MD Anderson Cancer Center), Yaohui Xu(University of Wisconsin Carbone Cancer Center), Beth McCullough(National Comprehensive Cancer Network), Mary A. Dwyer(National Comprehensive Cancer Network), Mai Q. Nguyen(National Comprehensive Cancer Network)
Cited by 141Open Access
Abstract
The NCCN Guidelines for Squamous Cell Skin Cancer provide recommendations for diagnostic workup, clinical stage, and treatment options for patients with cutaneous squamous cell carcinoma. The NCCN panel meets annually to discuss updates to the guidelines based on comments from panel members and the Institutional Review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new surgical recommendation terminology (peripheral and deep en face margin assessment), as well as recent updates on topical prophylaxis, immunotherapy for regional and metastatic disease, and radiation therapy.
Related Papers
No related papers found
Powered by citation graph analysis